NO20040991L - Andvendelse av hCG i kontrollert ovariehyperstimulering. - Google Patents

Andvendelse av hCG i kontrollert ovariehyperstimulering.

Info

Publication number
NO20040991L
NO20040991L NO20040991A NO20040991A NO20040991L NO 20040991 L NO20040991 L NO 20040991L NO 20040991 A NO20040991 A NO 20040991A NO 20040991 A NO20040991 A NO 20040991A NO 20040991 L NO20040991 L NO 20040991L
Authority
NO
Norway
Prior art keywords
hcg
ovarian hyperstimulation
controlled ovarian
rates
controlled
Prior art date
Application number
NO20040991A
Other languages
English (en)
Inventor
Yves Menezo
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20040991L publication Critical patent/NO20040991L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen tilveiebringer en protokoll som fører til forbedrede embryoimplantasjonsfrekvenser og/eller reduserte spontanabortfrekvenser i hvilke hCG, eller en bioanalog, blir administrert under den follikulære fase.
NO20040991A 2001-09-12 2004-03-08 Andvendelse av hCG i kontrollert ovariehyperstimulering. NO20040991L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01307757 2001-09-12
PCT/GB2002/004158 WO2003022302A2 (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Publications (1)

Publication Number Publication Date
NO20040991L true NO20040991L (no) 2004-03-08

Family

ID=8182261

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040991A NO20040991L (no) 2001-09-12 2004-03-08 Andvendelse av hCG i kontrollert ovariehyperstimulering.

Country Status (20)

Country Link
US (1) US7405197B2 (no)
EP (1) EP1425032A2 (no)
JP (1) JP2005501918A (no)
KR (1) KR20040032954A (no)
CN (1) CN100536912C (no)
AR (1) AR036592A1 (no)
BR (1) BR0212429A (no)
CA (1) CA2457849A1 (no)
EA (1) EA009330B1 (no)
HK (1) HK1067867A1 (no)
HR (1) HRP20040087A2 (no)
IL (1) IL160780A0 (no)
ME (1) MEP39208A (no)
MX (1) MXPA04002256A (no)
NO (1) NO20040991L (no)
PL (1) PL369098A1 (no)
RS (1) RS21004A (no)
UA (1) UA82650C2 (no)
WO (1) WO2003022302A2 (no)
ZA (1) ZA200400835B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596881B1 (en) * 2003-02-07 2008-12-10 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Use of human chorionic gonadotropin in the treatment of symptoms caused by endometriosis
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20150273020A1 (en) * 2007-05-11 2015-10-01 Lori R. Bernstein Hormone Normalization Therapy and Uses Therefor
ES2384677T3 (es) * 2009-04-23 2012-07-10 F. Hoffmann-La Roche Ag Procedimiento y aparato para la determinación de recomendaciones para dosificaciones de sustancias activas, en base a series de mediciones de, como mínimo, un parámetro fisiológico de un paciente
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
JP6087338B2 (ja) 2011-03-31 2017-03-01 フェリング ベスローテン フェンノートシャップ 医薬製剤
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) * 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
WO2013010840A2 (en) * 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
US20150290292A1 (en) 2012-10-18 2015-10-15 Neuralight Hd, Llc Treatment of Depression and PTSD
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CA3031252A1 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CA3035055A1 (en) 2016-08-29 2018-03-08 Progena, Inc. Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of ivf patient
RU2646578C1 (ru) * 2017-02-13 2018-03-05 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия им. С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ повышения эффективности имплантации эмбриона в естественном цикле зачатия и в протоколах вспомогательных репродуктивных технологий
CN109431647B (zh) * 2018-09-20 2020-10-30 华中农业大学 一种杂交水牛同期发情-定时输精的处理方法
CN114667141A (zh) 2019-09-03 2022-06-24 奥布赛瓦股份公司 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案
US20230102503A1 (en) 2020-02-10 2023-03-30 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
WO1998058657A1 (en) 1997-06-20 1998-12-30 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
ZA987497B (en) 1997-09-08 1999-02-23 Akzo Nobel Nv Expression of gonadotropins in dictyostelium
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
ATE317266T1 (de) 1999-02-24 2006-02-15 Novo Nordisk As In vitro methode zur synchronisation von oozytenreifung
BR0010709B1 (pt) * 1999-05-07 2011-11-29 uso de lh para a produção de um medicamento para induzir a paucifoliculogênese ou unifoliculogênese em mulheres anovulatórias.
CZ302835B6 (cs) 2000-01-27 2011-11-30 Laboratoires Serono Sa Farmaceutický prostredek

Also Published As

Publication number Publication date
CN1553808A (zh) 2004-12-08
PL369098A1 (en) 2005-04-18
MXPA04002256A (es) 2004-07-23
BR0212429A (pt) 2004-10-26
MEP39208A (en) 2011-02-10
UA82650C2 (uk) 2008-05-12
US7405197B2 (en) 2008-07-29
WO2003022302A3 (en) 2003-12-18
WO2003022302A2 (en) 2003-03-20
EA200400427A1 (ru) 2004-08-26
CA2457849A1 (en) 2003-03-20
IL160780A0 (en) 2004-08-31
ZA200400835B (en) 2005-04-26
RS21004A (en) 2006-12-15
HRP20040087A2 (en) 2004-12-31
EP1425032A2 (en) 2004-06-09
HK1067867A1 (en) 2005-04-22
KR20040032954A (ko) 2004-04-17
JP2005501918A (ja) 2005-01-20
AR036592A1 (es) 2004-09-22
EA009330B1 (ru) 2007-12-28
CN100536912C (zh) 2009-09-09
US20050065069A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
NO20040991L (no) Andvendelse av hCG i kontrollert ovariehyperstimulering.
CY1108747T1 (el) Παρασκευες ενος σουλφινυλο ακεταμιδιου
SE0100901D0 (sv) New composition
AU2003211688A1 (en) Method for controlling the stability of emulsions and stabilized emulsions
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
NO20030374L (no) Syklopentanoindoler, preparater som inneholder slike forbindelser og behandlingsfremgangsmåter
NO20032848D0 (no) Substituerte triazoldiaminderivater som kinaseinhibitorer
HK1067865A1 (en) Use of hcg and lh in controlled ovarian hyperstimulation
DK1513535T3 (da) Formulering til kontrolleret frisætning af lamotrigin
AP2004002995A0 (en) Combination therapy for the treatment of cancer
ATE457132T1 (de) Aromakonzentrate
DE60128701D1 (en) Claudin polypeptide
NO20035458D0 (no) Virkestoffkombinasjon av for eksempel galantamin eller desoksypeganin og for eksempel acamprosat eller memantin for behandling av enavhengighet slik som alkoholisme
UA87433C2 (ru) Гонадотропины для стимулирования фолликулогенеза
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
DK1383742T3 (da) Syntese og fremgangsmåder til anvendelse af tetrahydroindolonanaloge og derivater
DK1355906T3 (da) 2H-1-benzopyranderivater, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
WO2002017858A3 (en) Role of fosb in bone formation
WO2003093300A3 (en) Anti-microbial peptides and compositions
UA31270A (uk) Спосіб формування товстокишкового анастомозу
ES2168948A1 (es) Nueva aplicacion terapeutica de la silicona.
UA32263A (uk) Спосіб діагностики некрозу при гострій кишковій непрохідності

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application